1. Home
  2. SLDP vs URGN Comparison

SLDP vs URGN Comparison

Compare SLDP & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Solid Power Inc.

SLDP

Solid Power Inc.

HOLD

Current Price

$5.31

Market Cap

993.3M

Sector

Energy

ML Signal

HOLD

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

HOLD

Current Price

$22.99

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLDP
URGN
Founded
2011
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Electrical Products
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
993.3M
1.1B
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
SLDP
URGN
Price
$5.31
$22.99
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
8
Target Price
$7.00
$28.50
AVG Volume (30 Days)
10.0M
1.1M
Earning Date
11-04-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$19,802,000.00
$96,516,000.00
Revenue This Year
$27.38
$27.96
Revenue Next Year
$36.18
$123.02
P/E Ratio
N/A
N/A
Revenue Growth
9.85
8.00
52 Week Low
$0.68
$3.42
52 Week High
$8.86
$30.00

Technical Indicators

Market Signals
Indicator
SLDP
URGN
Relative Strength Index (RSI) 47.16 45.79
Support Level $4.78 $24.00
Resistance Level $5.33 $30.00
Average True Range (ATR) 0.37 1.76
MACD -0.04 -0.54
Stochastic Oscillator 42.77 5.74

Price Performance

Historical Comparison
SLDP
URGN

About SLDP Solid Power Inc.

Solid Power Inc is engaged in solid-state battery technology and manufacturing processes. Its core technology is a sulfide-based solid electrolyte material, which replaces the liquid or gel electrolyte used in traditional lithium-ion battery cells. Its commercialization plan is to manufacture and sell electrolytes to Tier 1 battery manufacturers and automotive original equipment manufacturers (OEMs) that choose to produce its battery cells.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

Share on Social Networks: